Zeiser, R. & Blazar, B. R. Acute graft-versus-host disease—biologic process, prevention, and therapy. N. Engl. J. Med. 377, 2167–2179 (2017).
Google Scholar
Kean, L. S. & Blazar, B. R. Major breakthroughs in hematopoietic stem cell transplantation and future challenges in clinical implementation. J. Clin. Invest. 134, e179944 (2024).
Google Scholar
Malard, F., Holler, E., Sandmaier, B. M., Huang, H. & Mohty, M. Acute graft-versus-host disease. Nat. Rev. Dis. Primers 9, 27 (2023).
Google Scholar
Penack, O. et al. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 11, e147–e159 (2024).
Google Scholar
Saliba, R. M. et al. Characteristics of graft-versus-host disease (GvHD) after post-transplantation cyclophosphamide versus conventional GvHD prophylaxis. Transplant. Cell. Ther. 28, 681–693 (2022).
Google Scholar
Greinix, H. T. et al. Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study. Haematologica 107, 1054–1063 (2022).
Google Scholar
Pidala, J. et al. Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. Blood 135, 97–107 (2020).
Google Scholar
Westin, J. R. et al. Steroid-refractory acute GVHD: predictors and outcomes. Adv. Hematol. 2011, 601953 (2011).
Google Scholar
Jagasia, M. et al. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood 135, 1739–1749 (2020).
Google Scholar
Zeiser, R. et al. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N. Engl. J. Med. 382, 1800–1810 (2020).
Google Scholar
Ferrara, J. L. M. & Deeg, H. J. Graft-versus-host disease. N. Engl. J. Med. 324, 667–674 (1991).
Google Scholar
Vriesendorp, H. M. & Heidt, P. J. History of graft-versus-host disease. Exp. Hematol. 44, 674–688 (2016).
Google Scholar
Neuerburg, C. K. F. et al. Antibiotic prophylaxis during allogeneic stem cell transplantation—a comprehensive single center retrospective analysis. Transplant. Cell. Ther. 30, 1195.e1–1195.e13 (2024).
Google Scholar
Zheng, D., Liwinski, T. & Elinav, E. Interaction between microbiota and immunity in health and disease. Cell Res. 30, 492–506 (2020).
Google Scholar
Taur, Y. et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin. Infect. Dis. 55, 905–914 (2012).
Google Scholar
Holler, E. et al. Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease. Biol. Blood Marrow Transplant. 20, 640–645 (2014).
Google Scholar
Taur, Y. et al. The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood 124, 1174–1182 (2014).
Google Scholar
Jenq, R. R. et al. Intestinal blautia is associated with reduced death from graft-versus-host disease. Biol. Blood Marrow Transplant. 21, 1373–1383 (2015).
Google Scholar
Shono, Y. et al. Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. Sci. Transl. Med. 8, 339ra371 (2016).
Google Scholar
Golob, J. L. et al. Stool microbiota at neutrophil recovery is predictive for severe acute graft vs host disease after hematopoietic cell transplantation. Clin. Infect. Dis. 65, 1984–1991 (2017).
Google Scholar
Peled, J. U. et al. Intestinal microbiota and relapse after hematopoietic-cell transplantation. J. Clin. Oncol. 35, 1650–1659 (2017).
Google Scholar
Weber, D. et al. Microbiota disruption induced by early use of broad-spectrum antibiotics is an independent risk factor of outcome after allogeneic stem cell transplantation. Biol. Blood Marrow Transplant. 23, 845–852 (2017).
Google Scholar
Hidaka, D. et al. The association between the incidence of intestinal graft-vs-host disease and antibiotic use after allogeneic hematopoietic stem cell transplantation. Clin. Transplant. 32, e13361 (2018).
Google Scholar
Peled, J. U. et al. Microbiota as predictor of mortality in allogeneic hematopoietic-cell transplantation. N. Engl. J. Med. 382, 822–834 (2020). This study demonstrates that increased intestinal microbiota diversity during the peri-engraftment phase is significantly associated with a reduced incidence of both overall mortality and transplant-related mortality following allo-HCT, based on an extensive analysis of faecal samples collected from four independent patient cohorts.
Google Scholar
Shono, Y. & van den Brink, M. R. M. Gut microbiota injury in allogeneic haematopoietic stem cell transplantation. Nat. Rev. Cancer 18, 283–295 (2018).
Google Scholar
Rashidi, A. et al. Randomized double-blind phase II trial of fecal microbiota transplantation versus placebo in allogeneic hematopoietic cell transplantation and AML. J. Clin. Oncol. 41, 5306–5319 (2023). This first randomized, double-blind, placebo-controlled trial of FMT in patients with acute myeloid leukaemia (AML) undergoing allo-HCT shows that oral encapsulated FMT safely improves microbiota diversity and restores depleted commensals after antibiotics, but does not reduce infection rates, providing key insights for future microbiome-targeted interventions.
Google Scholar
Gorshein, E. et al. Lactobacillus rhamnosus GG probiotic enteric regimen does not appreciably alter the gut microbiome or provide protection against GVHD after allogeneic hematopoietic stem cell transplantation. Clin. Transplant. 31, e12947 (2017).
Google Scholar
Rashidi, A. et al. Lasting shift in the gut microbiota in patients with acute myeloid leukemia. Blood Adv. 6, 3451–3457 (2022).
Google Scholar
Rashidi, A. et al. Gut dysbiosis during antileukemia chemotherapy versus allogeneic hematopoietic cell transplantation. Cancer 126, 1434–1447 (2020).
Google Scholar
Rafei, H. & Jenq, R. R. Microbiome-intestine cross talk during acute graft-versus-host disease. Blood 136, 401–409 (2020).
Google Scholar
Weber, D. et al. Low urinary indoxyl sulfate levels early after transplantation reflect a disrupted microbiome and are associated with poor outcome. Blood 126, 1723–1728 (2015).
Google Scholar
Stohs, E. J., Abbas, A. & Freifeld, A. Approach to febrile neutropenia in patients undergoing treatments for hematologic malignancies. Transpl. Infect. Dis. 26, e14236 (2024).
Google Scholar
Schwabkey, Z. I. et al. Diet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment. Sci. Transl. Med. 14, eabo3445 (2022).
Google Scholar
Rashidi, A. et al. Altered microbiota-host metabolic cross talk preceding neutropenic fever in patients with acute leukemia. Blood Adv. 5, 3937–3950 (2021).
Google Scholar
Spellman, S. R. et al. Current activity trends and outcomes in hematopoietic cell transplantation and cellular therapy—a report from the CIBMTR. Transplant. Cell. Ther. 31, 505–532 (2025).
Google Scholar
Vallet, N. et al. Circulating T cell profiles associate with enterotype signatures underlying hematological malignancy relapses. Cell Host Microbe 31, 1386–1403.e6 (2023).
Google Scholar
Jones, J. M., Wilson, R. & Bealmear, P. M. Mortality and gross pathology of secondary disease in germfree mouse radiation chimeras. Radiat. Res. 45, 577–588 (1971).
Google Scholar
Bekkum, D. W. V., Roodenburg, J., Heidt, P. J. & Waaij, D. V. D. Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora. J. Natl Cancer Inst. 52, 401–404 (1974).
Google Scholar
Burgos da Silva, M. et al. Preservation of the fecal microbiome is associated with reduced severity of graft-versus-host disease. Blood 140, 2385–2397 (2022). This study demonstrates that the abundance of anaerobes and butyrate producers at GVHD onset is positively associated with improved overall survival, including patients with lower-gastrointestinal GVHD.
Google Scholar
Thiele Orberg, E. et al. Bacteria and bacteriophage consortia are associated with protective intestinal metabolites in patients receiving stem cell transplantation. Nat. Cancer 5, 187–208 (2024). This study integrates microbiome, virome and metabolomic profiling in patients undergoing allo-HCT to identify a Lachnospiraceae and Oscillospiraceae–bacteriophage signature linked to IMM production and survival, and provides evidence for bacteriophage-encoded butyrate biosynthesis pathways.
Google Scholar
Payen, M. et al. Functional and phylogenetic alterations in gut microbiome are linked to graft-versus-host disease severity. Blood Adv. 4, 1824–1832 (2020).
Google Scholar
Hayase, E. et al. Bacteroides ovatus alleviates dysbiotic microbiota-induced graft-versus-host disease. Cell Host Microbe 32, 1621–1636.e6 (2024).
Google Scholar
El Jurdi, N. et al. Pre-transplant and longitudinal changes in faecal microbiome characteristics are associated with subsequent development of chronic graft-versus-host disease. Br. J. Haematol. 203, 288–294 (2023).
Google Scholar
Markey, K. A. et al. The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic GVHD. Blood 136, 130–136 (2020). This study demonstrates that the concentration of butyrate and proprionate in plasma could be associated with a risk reduction of cGVHD, suggesting that SCFAs could be used as biomarkers.
Google Scholar
Rashidi, A. et al. Oral and gut microbiome alterations in oral chronic GVHD disease: results from close assessment and testing for chronic GVHD (CATCH Study). Clin. Cancer Res. 30, 4240–4250 (2024).
Google Scholar
Kambara, Y. et al. Oral inflammation and microbiome dysbiosis exacerbate chronic graft-versus-host disease. Blood 145, 881–896 (2025).
Google Scholar
Habenicht, K. M. et al. Expansions of circulating plasmablasts producing commensal-reactive IgA antibodies are predictors for chronic GVHD. Blood 145, 3178–3188 (2025).
Google Scholar
Bergeron, A. et al. Effect of azithromycin on airflow decline-free survival after allogeneic hematopoietic stem cell transplant: the ALLOZITHRO randomized clinical trial. Jama 318, 557–566 (2017).
Google Scholar
Elgarten, C. W. et al. Broad-spectrum antibiotics and risk of graft-versus-host disease in pediatric patients undergoing transplantation for acute leukemia: association of carbapenem use with the risk of acute graft-versus-host disease. Transplant. Cell Ther. 27, 177.e1–177.e8 (2021).
Google Scholar
Lee, S. E. et al. Alteration of the intestinal microbiota by broad-spectrum antibiotic use correlates with the occurrence of intestinal graft-versus-host disease. Biol. Blood Marrow Transplant. 25, 1933–1943 (2019).
Google Scholar
Hayase, E. et al. Mucus-degrading bacteroides link carbapenems to aggravated graft-versus-host disease. Cell 185, 3705–3719.e14 (2022). This study shows that meropenem treatment exacerbates colonic GVHD in mice by promoting B. thetaiotaomicron-mediated mucin degradation, which thins the mucus layer, but oral xylose supplementation mitigates this effect, suggesting a nutritional strategy to counter antibiotic-induced microbiome injury in allo-HCT.
Google Scholar
Mathewson, N. D. et al. Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease. Nat. Immunol. 17, 505–513 (2016).
Google Scholar
Fujiwara, H. et al. Microbial metabolite sensor GPR43 controls severity of experimental GVHD. Nat. Commun. 9, 3674 (2018).
Google Scholar
Jørgensen, M. et al. Metabolic potential of the gut microbiome is significantly impacted by conditioning regimen in allogeneic hematopoietic stem cell transplantation recipients. Int. J. Mol. Sci. 23, 11115 (2022).
Google Scholar
Li, Y. et al. Differences in the establishment of gut microbiota and metabolome characteristics between Balb/c and C57BL/6J mice after proton irradiation. Front. Microbiology 13, 874702 (2022).
Google Scholar
Nguyen, C. L. et al. High-resolution analyses of associations between medications, microbiome, and mortality in cancer patients. Cell 186, 2705–2718.e17 (2023). This study develops PARADIGM, a computational framework applied to longitudinal microbiome and medication data from patients undergoing allo-HCT, to reveal drug–microbiota associations that predict clinical outcomes and uncover strain-level dynamics under antibiotic pressure.
Google Scholar
Fuji, S. et al. Severe weight loss in 3 months after allogeneic hematopoietic SCT was associated with an increased risk of subsequent non-relapse mortality. Bone Marrow Transplant. 50, 100–105 (2015).
Google Scholar
Zama, D. et al. Enteral versus parenteral nutrition as nutritional support after allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. Transplant. Cell Ther. 27, 180.e1–180.e8 (2021).
Google Scholar
Andersen, S. et al. Pilot study investigating the effect of enteral and parenteral nutrition on the gastrointestinal microbiome post-allogeneic transplantation. Br. J. Haematol. 188, 570–581 (2020).
Google Scholar
Schroeder, B. O. et al. Bifidobacteria or fiber protects against diet-induced microbiota-mediated colonic mucus deterioration. Cell Host Microbe 23, 27–40.e7 (2018).
Google Scholar
Ng, K. M. et al. Recovery of the gut microbiota after antibiotics depends on host diet, community context, and environmental reservoirs. Cell Host Microbe 28, 628 (2020).
Google Scholar
Parrish, A. et al. Akkermansia muciniphila exacerbates food allergy in fibre-deprived mice. Nat. Microbiol. 8, 1863–1879 (2023).
Google Scholar
So, D. et al. Dietary fiber intervention on gut microbiota composition in healthy adults: a systematic review and meta-analysis. Am. J. Clin. Nutr. 107, 965–983 (2018).
Google Scholar
Lindner, S. & Peled, J. U. Update in clinical and mouse microbiota research in allogeneic haematopoietic cell transplantation. Curr. Opin. Hematol. 27, 360–367 (2020).
Google Scholar
Wastyk, H. C. et al. Gut-microbiota-targeted diets modulate human immune status. Cell 184, 4137–4153.e14 (2021).
Google Scholar
Stein-Thoeringer, C. K. et al. Lactose drives Enterococcus expansion to promote graft-versus-host disease. Science 366, 1143–1149 (2019). This study concludes that the presence of lactose, a carbohydrate, can exacerbate the relative abundance of Enterococcus, a proteobacteria associated with poor outcomes post transplantation, demonstrating that a specific macronutrient can modulate the microbiome and outcomes in GVHD.
Google Scholar
Morello, E. et al. Nutritional strategies to improve VRE control. Transplant. Cell. Ther. 30, 548.e1–548.e4 (2024).
Google Scholar
Seike, K. et al. Ambient oxygen levels regulate intestinal dysbiosis and GVHD severity after allogeneic stem cell transplantation. Immunity 56, 353–368.e6 (2023).
Google Scholar
Donohoe, D. R. et al. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metab. 13, 517–526 (2011).
Google Scholar
Fujiwara, H. et al. Mitochondrial complex II in intestinal epithelial cells regulates T cell-mediated immunopathology. Nat. Immunol. 22, 1440–1451 (2021).
Google Scholar
Kelly, C. J. et al. Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function. Cell Host Microbe 17, 662–671 (2015).
Google Scholar
Lin, D. et al. Roles of the intestinal microbiota and microbial metabolites in acute GVHD. Exp. Hematol. Oncol. 10, 49 (2021).
Google Scholar
Koyama, M. et al. Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease. Nat. Med. 18, 135–142 (2012).
Google Scholar
Li, H. et al. Profound depletion of host conventional dendritic cells, plasmacytoid dendritic cells, and B cells does not prevent graft-versus-host disease induction. J. Immunol. 188, 3804–3811 (2012).
Google Scholar
Stephens, W. Z. et al. Epithelial–myeloid exchange of MHC class II constrains immunity and microbiota composition. Cell Rep. 37, 109916 (2021).
Google Scholar
Koyama, M. et al. MHC class II antigen presentation by the intestinal epithelium initiates graft-versus-host disease and is influenced by the microbiota. Immunity 51, 885–898.e7 (2019).
Google Scholar
Koyama, M. et al. Intestinal microbiota controls graft-versus-host disease independent of donor-host genetic disparity. Immunity 56, 1876–1893.e8 (2023). This study shows that the pre-transplant intestinal microbiota regulates ileal MHC class II expression and GVHD severity, identifies vancomycin-sensitive taxa as key MHC class II inducers and demonstrates that peri-transplant vancomycin mitigates CD4⁺ T cell-mediated GVHD, with similar microbiota–HLA class II associations observed in a large clinical cohort.
Google Scholar
Yeh, A. C. et al. Microbiota dictate T cell clonal selection to augment graft-versus-host disease after stem cell transplantation. Immunity 57, 1648–1664.e9 (2024). This work introduces a Bayesian model to interrogate donor and recipient TCR repertoires in mouse transplants, uncovering that microbiota-specific T cells drive clonotypic expansion and intensify GVHD by targeting microbial antigens, revealing a microbiota-dependent mechanism for GVHD beyond genetic disparity.
Google Scholar
Jarosch, S. et al. Multimodal immune cell phenotyping in GI biopsies reveals microbiome-related T cell modulations in human GvHD. Cell Rep. Med. 4, 101125 (2023).
Google Scholar
Schwab, L. et al. Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage. Nat. Med. 20, 648–654 (2014).
Google Scholar
Hülsdünker, J. et al. Neutrophils provide cellular communication between ileum and mesenteric lymph nodes at graft-versus-host disease onset. Blood 131, 1858–1869 (2018).
Google Scholar
Rückert, T. et al. Human β-defensin 2 ameliorates acute GVHD by limiting ileal neutrophil infiltration and restraining T cell receptor signaling. Sci. Transl. Med. 14, eabp9675 (2022).
Google Scholar
Peng, L., Li, Z. R., Green, R. S., Holzman, I. R. & Lin, J. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J. Nutr. 139, 1619–1625 (2009).
Google Scholar
Rooks, M. G. & Garrett, W. S. Gut microbiota, metabolites and host immunity. Nat. Rev. Immunol. 16, 341–352 (2016).
Google Scholar
Chelakkot, C., Ghim, J. & Ryu, S. H. Mechanisms regulating intestinal barrier integrity and its pathological implications. Exp. Mol. Med. 50, 1–9 (2018).
Google Scholar
Du, Y. et al. The role of short chain fatty acids in inflammation and body health. Int. J. Mol. Sci. 25, 7379 (2024).
Google Scholar
Kim, C. H. Control of lymphocyte functions by gut microbiota-derived short-chain fatty acids. Cell. Mol. Immunol. 18, 1161–1171 (2021).
Google Scholar
Golob, J. L. et al. Butyrogenic bacteria after acute graft-versus-host disease (GVHD) are associated with the development of steroid-refractory GVHD. Blood Adv. 3, 2866–2869 (2019).
Google Scholar
Kaiko, G. E. et al. The colonic crypt protects stem cells from microbiota-derived metabolites. Cell 165, 1708–1720 (2016).
Google Scholar
Scott, S. A., Fu, J. & Chang, P. V. Microbial tryptophan metabolites regulate gut barrier function via the aryl hydrocarbon receptor. Proc. Natl Acad. Sci. USA 117, 19376–19387 (2020).
Google Scholar
Zelante, T. et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity 39, 372–385 (2013).
Google Scholar
Collins, S. L., Stine, J. G., Bisanz, J. E., Okafor, C. D. & Patterson, A. D. Bile acids and the gut microbiota: metabolic interactions and impacts on disease. Nat. Rev. Microbiol. 21, 236–247 (2023).
Google Scholar
Sinha, S. R. et al. Dysbiosis-induced secondary bile acid deficiency promotes intestinal inflammation. Cell Host Microbe 27, 659–670.e5 (2020).
Google Scholar
Cipriani, S. et al. The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. PLoS ONE 6, e25637 (2011).
Google Scholar
Fathima, A. & Jamma, T. UDCA ameliorates inflammation driven EMT by inducing TGR5 dependent SOCS1 expression in mouse macrophages. Sci. Rep. 14, 24285 (2024).
Google Scholar
Holter, M. M., Chirikjian, M. K., Govani, V. N. & Cummings, B. P. TGR5 signaling in hepatic metabolic health. Nutrients 12, 2598 (2020).
Google Scholar
Mueller, M. et al. Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. J. Hepatol. 62, 1398–1404 (2015).
Google Scholar
Prayitno, K. & Bhat, M. Repurposing UDCA, an FXR inhibitor, to prevent SARS-Cov-2 infection. Gastroenterology 164, 1019–1020 (2023).
Google Scholar
Brevini, T. et al. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. Nature 615, 134–142 (2023).
Google Scholar
Michonneau, D. et al. Metabolomics analysis of human acute graft-versus-host disease reveals changes in host and microbiota-derived metabolites. Nat. Commun. 10, 5695 (2019).
Google Scholar
Haring, E. et al. Bile acids regulate intestinal antigen presentation and reduce graft-versus-host disease without impairing the graft-versus-leukemia effect. Haematologica 106, 2131–2146 (2021).
Google Scholar
Lindner, S. et al. Altered microbial bile acid metabolism exacerbates T cell-driven inflammation during graft-versus-host disease. Nat. Microbiol. 9, 614–630 (2024). This study is the first to show that the medication ursidiol (UDCA), an SBA, positively correlates with improved survival post allo-HCT and elucidates that UDCA can reduce proliferation of primary human T cells, contributing a mechanistic insight into bile acids and their immunomodulatory properties.
Google Scholar
Han, L. et al. Multi-omics analysis reveals a feedback loop amplifying immune responses in acute graft-versus-host disease due to imbalanced gut microbiota and bile acid metabolism. J. Transl. Med. 22, 746 (2024).
Google Scholar
Kovtonyuk, L. V. et al. IL-1 mediates microbiome-induced inflammaging of hematopoietic stem cells in mice. Blood 139, 44–58 (2022).
Google Scholar
Storb, R. et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. N. Engl. J. Med. 308, 302–307 (1983).
Google Scholar
Beelen, D. W., Elmaagacli, A., Müller, K. D., Hirche, H. & Schaefer, U. W. Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospective randomized trial. Blood 93, 3267–3275 (1999).
Google Scholar
Beelen, D. W. et al. Evidence that sustained growth suppression of intestinal anaerobic bacteria reduces the risk of acute graft-versus-host disease after sibling marrow transplantation. Blood 80, 2668–2676 (1992).
Google Scholar
Vossen, J. M. et al. Prevention of infection and graft-versus-host disease by suppression of intestinal microflora in children treated with allogeneic bone marrow transplantation. Eur. J. Clin. Microbiol. Infect. Dis. 9, 14–23 (1990).
Google Scholar
Severyn, C. J. et al. Microbiota dynamics in a randomized trial of gut decontamination during allogeneic hematopoietic cell transplantation. JCI Insight 7, e154344 (2022).
Google Scholar
Farowski, F. et al. Impact of choice, timing, sequence and combination of broad-spectrum antibiotics on the outcome of allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant. 53, 52–57 (2018).
Google Scholar
Han, L. et al. Intestinal microbiota can predict acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 25, 1944–1955 (2019).
Google Scholar
Weber, D. et al. Detrimental effect of broad-spectrum antibiotics on intestinal microbiome diversity in patients after allogeneic stem cell transplantation: lack of commensal sparing antibiotics. Clin. Infect. Dis. 68, 1303–1310 (2018).
Google Scholar
Tanaka, J. S. et al. Anaerobic antibiotics and the risk of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 26, 2053–2060 (2020).
Google Scholar
Rashidi, A. et al. Analysis of antibiotic exposure and development of acute graft-vs-host disease following allogeneic hematopoietic cell transplantation. JAMA Netw. Open 6, e2317188 (2023).
Google Scholar
Vehreschild, M. et al. An open randomized multicentre phase 2 trial to assess the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized patients treated with fluoroquinolones. J. Antimicrob. Chemother. 77, 1155–1165 (2022).
Google Scholar
Messaoudene, M. et al. The DAV132 colon-targeted adsorbent does not interfere with plasma concentrations of antibiotics but prevents antibiotic-related dysbiosis: a randomized phase I trial in healthy volunteers. Nat. Commun. 15, 8083 (2024).
Google Scholar
Kokai-Kun, J. F. et al. Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial. Lancet Infect. Dis. 19, 487–496 (2019).
Google Scholar
Menon, R. et al. Multi-omic profiling a defined bacterial consortium for treatment of recurrent Clostridioides difficile infection. Nat. Med. 31, 223–234 (2025).
Google Scholar
Fackelmann, G. et al. Gut microbiome signatures of vegan, vegetarian and omnivore diets and associated health outcomes across 21,561 individuals. Nat. Microbiol. 10, 41–52 (2025).
Google Scholar
Baumgartner, A. et al. Revisiting nutritional support for allogeneic hematologic stem cell transplantation—a systematic review. Bone Marrow Transplant. 52, 506–513 (2017).
Google Scholar
Arends, J. et al. ESPEN guidelines on nutrition in cancer patients. Clin. Nutr. 36, 11–48 (2017).
Google Scholar
Nava, T. et al. Supportive care during pediatric hematopoietic stem cell transplantation: beyond infectious diseases. A report from workshops on supportive care of the Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 55, 1126–1136 (2020).
Google Scholar
Peric, Z. et al. Variability of nutritional practices in peritransplant period after allogeneic hematopoietic stem cell transplantation: a survey by the complications and quality of life working party of the EBMT. Bone Marrow Transplant. 53, 1030–1037 (2018).
Google Scholar
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT02763033 (2025).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05067595 (2025).
Cohen, S. A. et al. Incidence and outcomes of bloodstream infections among hematopoietic cell transplant recipients from species commonly reported to be in over-the-counter probiotic formulations. Transpl. Infect. Dis. 18, 699–705 (2016).
Google Scholar
Jenq, R. R. et al. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J. Exp. Med. 209, 903–911 (2012).
Google Scholar
Gerbitz, A. et al. Probiotic effects on experimental graft-versus-host disease: let them eat yogurt. Blood 103, 4365–4367 (2004).
Google Scholar
Ladas, E. J. et al. The safety and feasibility of probiotics in children and adolescents undergoing hematopoietic cell transplantation. Bone Marrow Transplant. 51, 262–266 (2016).
Google Scholar
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT03057054 (2025).
Fukushima, K. et al. Clostridium butyricum MIYAIRI 588 contributes to the maintenance of intestinal microbiota diversity early after haematopoietic cell transplantation. Bone Marrow Transplant. 59, 795–802 (2024).
Google Scholar
Ponce, D. M. et al. Preliminary results of the open-label phase of a 2-part phase 1b study that evaluates safety, tolerability, pharmacokinetics, and efficacy of investigational microbiome therapeutic SER-155 in adults undergoing allogeneic hematopoietic cell transplantation (allo-HCT). Transplant. Cell. Ther. 30, S266 (2024).
Google Scholar
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04995653 (2024).
Wasilewski, A., Zielińska, M., Storr, M. & Fichna, J. Beneficial effects of probiotics, prebiotics, synbiotics, and psychobiotics in inflammatory bowel disease. Inflamm. Bowel Dis. 21, 1674–1682 (2015).
Google Scholar
Takai, A. et al. Fructo-oligosaccharides ameliorate steatohepatitis, visceral adiposity, and associated chronic inflammation via increased production of short-chain fatty acids in a mouse model of non-alcoholic steatohepatitis. BMC Gastroenterol. 20, 46 (2020).
Google Scholar
Andermann, T. M. et al. A fructo-oligosaccharide prebiotic is well tolerated in adults undergoing allogeneic hematopoietic stem cell transplantation: a phase I dose-escalation trial. Transplant. Cell Ther. 27, 932.e1–932.e11 (2021).
Google Scholar
Yazdandoust, E. et al. Gut microbiota intervention by pre and probiotics can induce regulatory T cells and reduce the risk of severe acute GVHD following allogeneic hematopoietic stem cell transplantation. Transpl. Immunol. 78, 101836 (2023).
Google Scholar
Iyama, S. et al. Efficacy of enteral supplementation enriched with glutamine, fiber, and oligosaccharide on mucosal injury following hematopoietic stem cell transplantation. Case Rep. Oncol. 7, 692–699 (2014).
Google Scholar
Upadhyaya, B. et al. Impact of dietary resistant starch type 4 on human gut microbiota and immunometabolic functions. Sci. Rep. 6, 28797 (2016).
Google Scholar
Venkataraman, A. et al. Variable responses of human microbiomes to dietary supplementation with resistant starch. Microbiome 4, 33 (2016).
Google Scholar
Yoshifuji, K. et al. Prebiotics protect against acute graft-versus-host disease and preserve the gut microbiota in stem cell transplantation. Blood Adv. 4, 4607–4617 (2020).
Google Scholar
Riwes, M. M. et al. Feasibility of a dietary intervention to modify gut microbial metabolism in patients with hematopoietic stem cell transplantation. Nat. Med. 29, 2805–2813 (2023). This clinical trial is the first to show feasibility of the use of a dietary supplement, resistant starch (fibre), to modulate the intestinal microbiome and the metabolome of patients undergoing allo-HCT.
Google Scholar
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT06102213 (2024).
Russo, E. et al. Immunomodulating activity and therapeutic effects of short chain fatty acids and tryptophan post-biotics in inflammatory bowel disease. Front. Immunol. 10, 2754 (2019).
Google Scholar
Gill, P. A., van Zelm, M. C., Muir, J. G. & Gibson, P. R. Review article: short chain fatty acids as potential therapeutic agents in human gastrointestinal and inflammatory disorders. Aliment. Pharmacol. Ther. 48, 15–34 (2018).
Google Scholar
Feuerstadt, P. et al. SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection. N. Engl. J. Med. 386, 220–229 (2022).
Google Scholar
Khanna, S. et al. Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double-blind, placebo-controlled trial with a bayesian primary analysis for the prevention of recurrent Clostridioides difficile infection. Drugs 82, 1527–1538 (2022).
Google Scholar
Webb, B. J. et al. Fecal microbiota transplantation for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients. Transpl. Infect. Dis. 18, 628–633 (2016).
Google Scholar
Innes, A. J. et al. Fecal microbiota transplant mitigates adverse outcomes seen in patients colonized with multidrug-resistant organisms undergoing allogeneic hematopoietic cell transplantation. Front. Cell. Infect. Microbiol. 11, 684659 (2021).
Google Scholar
Su, F. et al. Tandem fecal microbiota transplantation cycles in an allogeneic hematopoietic stem cell transplant recipient targeting carbapenem-resistant Enterobacteriaceae colonization: a case report and literature review. Eur. J. Med. Res. 26, 37 (2021).
Google Scholar
DeFilipp, Z. et al. Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. N. Engl. J. Med. 381, 2043–2050 (2019).
Google Scholar
DeFilipp, Z. et al. Third-party fecal microbiota transplantation for high-risk treatment-naïve acute GVHD of the lower GI tract. Blood Adv. 8, 2074–2084 (2024).
Google Scholar
Taur, Y. et al. Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant. Sci. Transl. Med. 10, eaap9489 (2018).
Google Scholar
van Lier, Y. F. et al. Donor fecal microbiota transplantation ameliorates intestinal graft-versus-host disease in allogeneic hematopoietic cell transplant recipients. Sci. Transl. Med. 12, eaaz8926 (2020).
Google Scholar
Zhao, Y. et al. Safety and efficacy of fecal microbiota transplantation for grade IV steroid refractory GI-GvHD patients: interim results from FMT2017002 trial. Front. Immunol. 12, 678476 (2021).
Google Scholar
Kakihana, K. et al. Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut. Blood 128, 2083–2088 (2016).
Google Scholar
Spindelboeck, W. et al. Antibiotic use and ileocolonic immune cells in patients receiving fecal microbiota transplantation for refractory intestinal GvHD: a prospective cohort study. Ther. Adv. Hematol. 12, 20406207211058333 (2021).
Google Scholar
Goeser, F. et al. Fecal microbiota transfer for refractory intestinal graft-versus-host disease—experience from two German tertiary centers. Eur. J. Haematol. 107, 229–245 (2021).
Google Scholar
Battipaglia, G. et al. Fecal microbiota transplantation before or after allogeneic hematopoietic transplantation in patients with hematologic malignancies carrying multidrug-resistance bacteria. Haematologica 104, 1682–1688 (2019).
Google Scholar
Spindelboeck, W. et al. Repeated fecal microbiota transplantations attenuate diarrhea and lead to sustained changes in the fecal microbiota in acute, refractory gastrointestinal graft-versus-host-disease. Haematologica 102, e210–e213 (2017).
Google Scholar
Liu, Y. et al. Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD. Exp. Hematol. Oncol. 11, 96 (2022).
Google Scholar
DeFilipp, Z. et al. Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity. Blood Adv. 2, 745–753 (2018).
Google Scholar
Zheng, Y. Y. et al. Clinical study of 19 cases of steroid-refractory gastrointestinal acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with fecal microbiota transplantation [Chinese]. Zhonghua Xue Ye Xue Za Zhi 44, 401–407 (2023).
Google Scholar
Goloshchapov, O. et al. Fecal microbiota transplantation for graft-versus-host disease in children and adults: methods, clinical effects, safety. Terapevticheskii arkhiv 92, 43–54 (2020).
Google Scholar
Rashidi, A. et al. Potential of fecal microbiota transplantation to prevent acute GVHD: analysis from a phase II trial. Clin. Cancer Res. 29, 4920–4929 (2023).
Google Scholar
Reddi, S. et al. Fecal microbiota transplantation to prevent acute graft-versus-host disease: pre-planned interim analysis of donor effect. Nat. Commun. 16, 1034 (2025).
Google Scholar
Malard, F. et al. Pooled allogeneic faecal microbiota MaaT013 for steroid-resistant gastrointestinal acute graft-versus-host disease: a single-arm, multicentre phase 2 trial. EClinicalMedicine 62, 102111 (2023). This HERACLES trial prospective phase II study evaluates MaaT013, a pooled allogeneic faecal microbiota product, in steroid-refractory gastrointestinal aGVHD, showing that treatment is safe and associated with clinical responses and increased microbiota richness in some patients, supporting further investigation of microbiome-based therapy for allo-HCT.
Google Scholar
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04769895 (2024).
Malard, F. et al. MaaT013 for ruxolitinib-refractory acute graft-versus-host disease with gastrointestinal involvement: results from the ARES phase III trial. Blood 146, 817–817 (2025).
Google Scholar
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT03078010 (2025).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT06026371?cond=GVHD,Acute&term=Prevention&intr=FMT&rank=4 (2026).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04745221 (2025).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT03819803 (2025).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04935684 (2023).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT02269150 (2025).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT03719092 (2025).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05111834 (2025).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04373057 (2025).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04263597 (2025).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04177004 (2025).
Ubeda, C. et al. Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. J. Clin. Invest. 120, 4332–4341 (2010).
Google Scholar
Harris, B. et al. Gut microbiota predict pulmonary infiltrates after allogeneic hematopoietic cell transplantation. Am. J. Respir. Crit. Care Med. 194, 450–463 (2016).
Google Scholar
Schluter, J. et al. The gut microbiota is associated with immune cell dynamics in humans. Nature 588, 303–307 (2020).
Google Scholar
Andrlová, H. et al. MAIT and Vδ2 unconventional T cells are supported by a diverse intestinal microbiome and correlate with favorable patient outcome after allogeneic HCT. Sci. Transl. Med. 14, eabj2829 (2022).
Google Scholar
Miltiadous, O. et al. Early intestinal microbial features are associated with CD4 T-cell recovery after allogeneic hematopoietic transplant. Blood 139, 2758–2769 (2022).
Google Scholar
Bunnett, N. W. Neuro-humoral signalling by bile acids and the TGR5 receptor in the gastrointestinal tract. J. Physiol. 592, 2943–2950 (2014).
Google Scholar
Parks, O. B., Pociask, D. A., Hodzic, Z., Kolls, J. K. & Good, M. Interleukin-22 signaling in the regulation of intestinal health and disease. Front. Cell Dev. Biol. 3, 85 (2015).
Google Scholar
Zhang, F., Aschenbrenner, D., Yoo, J. Y. & Zuo, T. The gut mycobiome in health, disease, and clinical applications in association with the gut bacterial microbiome assembly. Lancet Microbe 3, e969–e983 (2022).
Google Scholar
Pargin, E. et al. The human gut virome: composition, colonization, interactions, and impacts on human health. Front. Microbiol. 14, 963173 (2023).
Google Scholar
Cao, Z. et al. The gut virome: a new microbiome component in health and disease. eBioMedicine 81, 104113 (2022).
Google Scholar
Iliev, I. D. & Cadwell, K. Effects of intestinal fungi and viruses on immune responses and inflammatory bowel diseases. Gastroenterology 160, 1050–1066 (2021).
Google Scholar
Legoff, J. et al. The eukaryotic gut virome in hematopoietic stem cell transplantation: new clues in enteric graft-versus-host disease. Nat. Med. 23, 1080–1085 (2017).
Google Scholar
Neri, U. et al. Expansion of the global RNA virome reveals diverse clades of bacteriophages. Cell 185, 4023–4037.e18 (2022).
Google Scholar
Hsu, B. B. et al. Dynamic modulation of the gut microbiota and metabolome by bacteriophages in a mouse model. Cell Host Microbe 25, 803–814.e5 (2019).
Google Scholar
Zuo, T. et al. Bacteriophage transfer during faecal microbiota transplantation in Clostridium difficile infection is associated with treatment outcome. Gut 67, 634–643 (2018).
Google Scholar
Rolling, T. et al. Haematopoietic cell transplantation outcomes are linked to intestinal mycobiota dynamics and an expansion of Candida parapsilosis complex species. Nat. Microbiol. 6, 1505–1515 (2021).
Google Scholar
van der Velden, W. J. F. M. et al. Role of the mycobiome in human acute graft-versus-host disease. Biol. Blood Marrow Transplant. 19, 329–332 (2013).
Google Scholar
